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Purpose: The purposed of this study was to investigate the fibroblast growth factor receptor 2 (FGFR2) gene in one
Chinese family with Crouzon syndrome and to characterize the related clinical features.
Methods: One family underwent complete ophthalmic examinations, and two patients were diagnosed with Crouzon
syndrome. Genomic DNA was extracted from leukocytes of peripheral blood collected from the family and 100 unrelated
control subjects from the same population. Exons 8 and 10 of FGFR2 were amplified by polymerase chain reaction (PCR)
and  directly  sequenced.  We  performed  ophthalmic  examinations,  including  best-corrected  visual  acuity,  slit-lamp
examination, fundus examination, Pentacam, Goldmann perimetry, and computed tomography (CT) of the skull.
Results: The two patients were affected with shallow orbits and ocular proptosis, accompanied by midface hypoplasia,
craniosynostosis, and clinically normal hands and feet. A heterozygous FGFR2 missense mutation c.866A>C (Gln289Pro)
in exon 8 was identified in the affected individuals, but not in any of the unaffected family members and the normal
controls.
Conclusions: Although FGFR2 mutations and polymorphisms have been reported in various ethnic groups, especially in
the area of osteology, we report, for the first time, the identification of one new FGFR2 mutation in Chinese patients with
Crouzon syndrome.
Crouzon  syndrome  (CS),  the  most  common
craniosynostosis  syndrome,  is  an  autosomal-dominant
inherited disorder, characterized by craniosynostosis, shallow
orbits, ocular proptosis, midface hypoplasia, and a curved,
beaklike nose [1-4].
Although this disorder is caused by the premature fusion
of  cranial  sutures,  leading  to  the  clinical  condition  of
craniosynostosis, which falls under the category of osteology,
many patients would choose ophthalmology, due to the ocular
proptosis and exposure keratitis. Until now, it was known that
craniosynostosis  is  related  to  the  fibroblast  growth  factor
receptors (FGFRs).
Fibroblast  growth  factors  (FGFs)  and  their  receptors
(FGFRs)  constitute  an  elaborate  signaling  system  that  is
involved in the developmental processes of most mammalian
tissues. FGFRs are transmembrane proteins consisting of an
extracellular ligand-binding domain and composed of three
immunoglobulin (Ig)-like domains, a transmembrane domain,
and an intracellular domain, which carries tyrosine kinase
activity. Ligand-binding specificity of FGFRs depends on the
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third  extracellular  Ig-like  domain,  which  is  subject  to
alternative splicing, which generates a variety of receptor
isoforms. Three different splice variants, IgIIIa, IgIIIb, and
IgIIIc, have been identified [5,6].
It is known that Crouzon syndrome is usually caused by
mutations in the FGFR2 gene located on chromosome 10q26.
Over 50 different mutations have been described in Crouzon
syndrome [1,7-12], with approximately 95% of cases having
mutations in just two exons of the gene, IIIa (8) and IIIc (10),
which  encode  the  extracellular  immunoglobulin-like  III
(IgIII) domain of the protein [13].
This  study  reported  the  mutational  analysis  of  one
Chinese family with Crouzon syndrome at the gene level,
along  with  related  clinical  features,  and  identified  one
heterozygous mutation.
METHODS
The Crouzon syndrome family: Two patients in one Chinese
family  (Figure  1)  were  diagnosed  as  having  Crouzon
syndrome  at  the  Zhongshan  Ophthalmic  Center.  We
performed  ophthalmic  examinations,  as  follows:  Visual
acuity  was  examined  using  the  ETDRS  chart  (Precision
Vision, La Salle, IL). An anterior segment photograph was
obtained  using  a  BX  900  Slit  Lamp  (Haag-Streit,  Bern,
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449Switzerland).  Anterior  segment  measurements  were
measured with Pentacam HR version 70700 (Oculus, Wetzlar,
Germany).  In  addition,  computed  tomography  (CT)  and
physical examinations were performed to exclude systemic
diseases.
Sample collection: The affected family was identified at the
Zhongshan Ophthalmic Center. One hundred subjects without
Figure  1.  The  pedigree  of  a  Chinese
family with Crouzon syndrome. Squares
denote  males,  and  circles  denote
females. The shaded symbols indicate
ophthalmologist-confirmed  Crouzon
syndrome.  The  arrow  points  to  the
proband.
TABLE 1. PRIMERS USED FOR PCR.
Exon Forward (5′-3′) Reverse (5′-3′) Product
size (bp)
Annealing
temperature (°C)
FGFR2-8 (IIIa) GGTCTCTCATTCTCCCATCCC CCAACAGGAAATCAAAGAACC 325 61
FGFR2-10 (IIIc) CCTCCACAATCATTCCTGTGTC ATAGCAGTCAACCAAGAAAAGGG 257 61
               Summary of the primers and products length used for the amplification of the exons of FGFR 2.
Figure 2. Photographs of II-3 (A) and
III-1  (B).  Both  patients  have  ocular
proptosis and midface hypoplasia.
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450diagnostic  features  of  Crouzon  syndrome,  from  the  same
population, were recruited to serve as normal controls. After
informed  consent  was  obtained  from  all  participating
individuals, following the principles of the Declaration of
Helsinki, venous blood samples were collected for genomic
DNA  extraction  from  peripheral  blood  leucocytes,  using
standard protocols.
Mutation detection: Exons 8 and 10 of the FGFR2 gene were
amplified by polymerase chain reaction (PCR) with primers
[14] (Table 1). Briefly, PCR was conducted in 50-μl reactions.
The cycling profile included one cycle at 94 °C for 5 min,
followed by 40 cycles at 94 °C for 45 s, 52–66 °C for 45 s,
and 72 °C for 45 s, as well as one cycle at 72 °C for 10 min.
The PCR products were sequenced from both directions with
an ABI3730 Automated Sequencer (PE Biosystems, Foster
City,  CA).  The  sequencing  results  were  analyzed  using
Chromas (version 2.3; Technelysium Pty Ltd, Brisbane, QLD,
Australia),  and  they  were  compared  with  the  reference
sequences  in  the  database  at  the  National  Center  for
Biotechnology Information (NCBI NC_000010).
The superimposed mutant PCR products were subcloned
into pGEM-T vector (Promega, Madison, WI) and sequenced
to identify the mutation. Briefly, PCR products were purified
by gel extraction, using gel extraction kits (Axygen, Union
City, CA) according to the manufacturer's instructions. The
purified PCR fragments were ligated into the pGEM-T easy
vector (Invitrogen, Carlsbad, CA), and the resulting plasmids
were  transfected,  by  heat  shock,  into  DH5a-competent
Escherichia  coli  for  propagation.  The  plasmid  DNA  was
sequenced using the ABI3700 and the T7 primer. Sequences
were determined with the DNAman software analysis system
(Lynnon Corporation, Quebec, Canada).
RESULTS
Clinical data: The Chinese family studied in this report was
from the southern area of China. Two individuals, in two
successive  generations,  were  found  to  have  the  same
Figure 3. Examination results of II-3 and
III-1. A: Anterior segment photograph
of II-3. B: Anterior segment photograph
of III-1. C: The anterior segment picture
of II-3 by Pentacam. D: The anterior
segment picture of III-1 by Pentacam.
E,  F:  Shallow  orbits  and  ocular
proptosis  of  III-1  using  computed
tomography (CT).
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451congenital  disease  (Figure  1).  These  patients  had  shallow
orbits  and  ocular  proptosis,  accompanied  by  midface
hypoplasia, craniosynostosis, a curved, beaklike nose, and
clinically normal hands and feet. They have had normal vision
since early childhood, but they displayed a surprised look
(Figure  2).  Applanation  tonometry  revealed  normal
intraocular  pressures  in  both  eyes  of  both  patients.  The
corneas were normal in size and transparency, and the lenses
were positioned normally and remained clear (Figure 3A,B).
The visual acuity, of the II-3 patient (30 years old, female)
as measured by LogMAR, was 0.10 (OD) and 0.10 (OS). The
axial lengths of II-3 were 21.99 mm (OD) and 22.13 mm (OS).
No  abnormalities  were  detected  in  the  lenses,  retinas,
choroids, or optic nerves. The eye prominence of II-3 was
19  mm  (OD)  and  20  mm  (OS).  The  anterior  segment
photograph is shown in Figure 3C—the anterior chamber
depths were 2.41 mm (OD) and 2.47 mm (OS).
The visual acuity of the III-1 patient (7 years old, male)
was 0.0 (OD) and 0.0 (OS). Axial lengths were 22.32 mm
(OD) and 22.25 mm (OS). No abnormalities were detected in
the lenses, retinas, choroids, or optic nerves. The anterior
segment  photograph  is  shown  in  Figure  3D;  the  anterior
chamber depths were 2.57 mm (OD) and 2.64 mm (OS). The
prominence of the III-1 was 17 mm (OD) and 16 mm (OS).
Computed tomography (CT) of the skull of III-1 (Figure
3E,F) was performed at 7 years of age, revealing shallow
orbits.
Mutation screening: A heterozygous missense mutation c.
866A>C (Gln289Pro) in exon 8 (Figure 4) was identified in
the two affected individuals, but not in any of the unaffected
Figure 4. DNA sequence of a part of
FGF2  in  the  affected  patients  and
unaffected individuals. A: A mutation c.
866A>C (Gln289Pro) in exon 8 in the
affected individuals. B: Sequence of the
normal allele of exon 8 subcloned into
the pGEM-T vector used as a control.
C: A heterozygous missense mutation c.
866A>C (Gln289Pro) in exon 8 in the
affected  individuals.  The  mutation
causes the glutarnine 289 codon (CAG)
to change to a proline codon (CCG).
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452family members and the normal controls. The mutation causes
the Glutarnine 289 codon (CAG) to change to a Proline codon
(CCG).
DISCUSSION
In  this  study,  we  found  one  mutation  in  exon  8  of  the
FGFR2 gene that is associated with Crouzon Syndrome: c.
866A>C. This mutation, rather than a rare polymorphism in
the normal population, is the causative mutation in the family.
The c.866A>C mutation (Gln289Pro) was identified for
the  ﬁrst  time  in  FGFR2  in  Chinese  patients;  however,  it
occurred at a hotspot for mutations, which have been found in
other ethnic groups [14].
Previously described mutations causing craniosynostosis
are  widely  distributed  across  the  FGFR2  protein,  yet  the
majority localize in some amino acids that form the S-S bond
in the IgIIIa/IIIc domain [14]. Severe phenotypes have been
associated with mutations, causing loss or addition of cysteine
residues, thereby resulting in the disruption of the protein’s
structure, dimerization, and activation of the receptor [15].
Kress  et  al.  [10]  found  that  some  mutations,  such  as
Gln289Pro,  Phe276Val,  Ile288Ser,  and  Thr341Pro,  affect
conserved residues in the IgIII loop or at its margins, and may
reduce the stability of the core loop domain, as suggested by
three-dimensional modeling of the IgIII FGFR2 domain [16].
The ocular manifestations in the conditions caused by
FGFR mutations included downslanting palpebral fissures,
shallow orbits and proptosis, hypertelorism, and strabismus.
Okajima  et  al.  [17]  reported  that  some  patients  with  an
FGFR2 mutation had ocular anterior chamber dysgenesis,
including  Peters  anomaly,  optic  nerve  hypoplasia,
scleralization  of  the  cornea,  and  corectopia  in
craniosynostosis syndromes. Fortunately, the patients in our
study did not have serious ocular disorders.
Actually, Chow et al. [18] and Robinson et al. [19] have
already found that FGFRs may play an important role in
regulating  anteroposterior  patterns  of  lens  cell  behavior.
Transgenic  expression  of  dominant-negative  Fgfrs  in  the
lenses  of  mice  resulted  in  reduced  fiber  cell  elongation.
However, few patients with FGFR mutations had congenital
cataracts, as in our study.
In summary, this study identified one novel mutation of
FGFR2 in a Chinese family with Crouzon syndrome. This
finding  expands  the  mutation  spectrum  of  FGFR2  and  is
useful  and  valuable  for  genetic  counseling  and  prenatal
diagnosis in families with Crouzon syndrome without serious
ocular disorders.
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